{
  "id": 15608959,
  "title": "3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.",
  "url": "https://urgent.news/2026/10/19/3-wall-street-analysts-see-intuitive-surgical-hitting-500-heres-the",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T13:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/19/3-wall-street-analysts-see-intuitive-surgical-500/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Three Wall Street analysts believe Intuitive Surgical (ISRG) stock will hit $500, according to a report. Oppenheimer upgraded the stock to Outperform in August, setting a $500 price target. Citigroup and Baird also set a $500 target in July while maintaining Buy and Outperform ratings. The company's success hinges on its ecosystem of surgical robots and recurring revenue from instruments, accessories, and servicing. Intuitive's da Vinci 5 platform, with improved imaging and computing capabilities, is expected to boost sales. Hospital adoption of the da Vinci systems is growing, with a 15% increase in procedures and an 18% rise in related revenue. The company's Ion platform also offers additional growth opportunities. Despite the bullish outlook, risks include slower procedure growth and strong competition. With strong earnings growth, the stock could potentially reach $500.",
  "summary": "Robotic surgery is growing, procedures are climbing, and da Vinci 5 is rolling out. Is Intuitive Surgical's premium valuation worth paying?",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}